普通外科指南

订阅

MedSci主页 / 所有栏目 / 普通外科指南

聚桂醇®内痔硬化注射疗法专家共识（2021版）

2021-06-30 《结直肠肛门外科》杂志编辑委员会组织制定 结直肠肛门外科

内痔硬化注射疗法

聚桂醇®内痔硬化注射疗法专家共识（2021版）

中文标题：

聚桂醇®内痔硬化注射疗法专家共识（2021版）

发布机构：

《结直肠肛门外科》杂志编辑委员会组织制定

发布日期：

2021-06-30

简要介绍：

为了进一步规范聚桂醇®硬化注射疗法的临床应用，使患者获得微创、痛苦小、恢复快且并发症少的治疗效果，《结直肠肛门外科》杂志编辑委员会结合我国目前内痔硬化注射疗法的研究现状，多次组织国内肛肠外科、内镜治疗专家通过网上问卷调查、专家意见讨论会等方式对聚桂醇®内痔硬化注射疗法的适应证、禁忌证、剂量、注射方法等内容进行专题研讨，最终形成《聚桂醇®内痔硬化注射疗法专家共识（2021版）》以指导临床应用。

相关资料下载：
[AttachmentFileName(sort=1, fileName=聚桂醇®内痔硬化注射疗法专家共识（2021版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ff9211c0022100d7, title=聚桂醇®内痔硬化注射疗法专家共识（2021版）, enTitle=, guiderFrom=结直肠肛门外科, authorId=0, author=, summary=聚桂醇®内痔硬化注射疗法专家共识（2021版）, cover=https://img.medsci.cn/20211016/1634393145876_5579292.jpg, journalId=0, articlesId=null, associationId=2015, associationName=《结直肠肛门外科》杂志编辑委员会组织制定, associationIntro=《结直肠肛门外科》杂志编辑委员会组织制定, copyright=0, guiderPublishedTime=Wed Jun 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">为了进一</span><span style="color: #373737;">步规范聚桂醇&reg;硬化注射疗法的临床应用，使患者获</span><span style="color: #373737;">得微创、痛苦小、恢复快且并发症少的治疗效果，</span><span style="color: #373737;">《结直肠肛门外科》杂志编辑委员会结合我国目前内</span><span style="color: #373737;">痔硬化注射疗法的研究现状，多次组织国内肛肠外</span><span style="color: #373737;">科、内镜治疗专家通过网上问卷调查、专家意见讨</span><span style="color: #373737;">论会等方式对聚桂醇&reg;内痔硬化注射疗法的适应证、</span><span style="color: #373737;">禁忌证、剂量、注射方法等内容进行专题研讨，最</span><span style="color: #373737;">终形成《聚桂醇&reg;内痔硬化注射疗法专家共识（2021</span><span style="color: #373737;">版）》以指导临床应用。</span></p>, tagList=[TagDto(tagId=116071, tagName=内痔硬化注射疗法)], categoryList=[CategoryDto(categoryId=23, categoryName=普通外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=76423, guiderKeyword=聚桂醇硬化剂, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3169, appHits=61, showAppHits=0, pcHits=773, showPcHits=3108, likes=0, shares=1, comments=5, approvalStatus=1, publishedTime=Sat Oct 16 22:29:55 CST 2021, publishedTimeString=2021-06-30, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Oct 16 22:08:58 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 17:41:34 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=聚桂醇®内痔硬化注射疗法专家共识（2021版）.pdf)])
聚桂醇®内痔硬化注射疗法专家共识（2021版）.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1077231, encodeId=1bcd10e72314e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq65GoIzj6QEruzBIUHx2tCkhjEYh6ZicZ3hhk4eclxR6POmDmnZp5FrMNAckgXER39xhZiaSkh7uDA/132, createdBy=21f05248050, createdName=大白9968, createdTime=Mon Dec 06 07:01:56 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067712, encodeId=d584106e712bb, content=很好啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9665476262, createdName=ms2000000522654746, createdTime=Sun Nov 07 02:35:37 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061145, encodeId=2540106114543, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17185603635, createdName=qijiaming, createdTime=Sun Oct 17 00:20:54 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061134, encodeId=01a21061134e6, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 23:07:46 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-12-06 大白9968

    感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1077231, encodeId=1bcd10e72314e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq65GoIzj6QEruzBIUHx2tCkhjEYh6ZicZ3hhk4eclxR6POmDmnZp5FrMNAckgXER39xhZiaSkh7uDA/132, createdBy=21f05248050, createdName=大白9968, createdTime=Mon Dec 06 07:01:56 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067712, encodeId=d584106e712bb, content=很好啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9665476262, createdName=ms2000000522654746, createdTime=Sun Nov 07 02:35:37 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061145, encodeId=2540106114543, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17185603635, createdName=qijiaming, createdTime=Sun Oct 17 00:20:54 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061134, encodeId=01a21061134e6, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 23:07:46 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-11-07 ms2000000522654746

    很好啊

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1077231, encodeId=1bcd10e72314e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq65GoIzj6QEruzBIUHx2tCkhjEYh6ZicZ3hhk4eclxR6POmDmnZp5FrMNAckgXER39xhZiaSkh7uDA/132, createdBy=21f05248050, createdName=大白9968, createdTime=Mon Dec 06 07:01:56 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067712, encodeId=d584106e712bb, content=很好啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9665476262, createdName=ms2000000522654746, createdTime=Sun Nov 07 02:35:37 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061145, encodeId=2540106114543, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17185603635, createdName=qijiaming, createdTime=Sun Oct 17 00:20:54 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061134, encodeId=01a21061134e6, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 23:07:46 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-17 qijiaming

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1077231, encodeId=1bcd10e72314e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq65GoIzj6QEruzBIUHx2tCkhjEYh6ZicZ3hhk4eclxR6POmDmnZp5FrMNAckgXER39xhZiaSkh7uDA/132, createdBy=21f05248050, createdName=大白9968, createdTime=Mon Dec 06 07:01:56 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067712, encodeId=d584106e712bb, content=很好啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9665476262, createdName=ms2000000522654746, createdTime=Sun Nov 07 02:35:37 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061145, encodeId=2540106114543, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17185603635, createdName=qijiaming, createdTime=Sun Oct 17 00:20:54 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061134, encodeId=01a21061134e6, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b12884021, createdName=1921987096, createdTime=Sat Oct 16 23:07:46 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 1921987096

    谢谢

    0

拓展阅读

聚桂醇硬化剂治疗口腔颌面部血管瘤和脉管畸形专家共识

中华口腔医学会(CSA,Chinese Stomatological Association) · 2018-05-15